Status:

UNKNOWN

The Effect of ePRO on Quality of Life and Prognosis of Patients With Unresectable Metastatic Colorectal Cancer

Lead Sponsor:

Harbin Medical University

Conditions:

Colorectal Cancer Metastatic

Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Bevacizumab combined with fluorouracil-based chemotherapy is the first-line standard treatment for patients with metastatic colorectal cancer (mCRC). However, some research show that the long-term sur...

Eligibility Criteria

Inclusion

  • Patients must have informed consent form (ICF) signed for the study
  • Patients must be ≥18 years old when signing the ICF
  • Histologically or cytologically-diagnosed unresectable metastatic colorectal cancer
  • Patients must receive bevacizumab combined with chemotherapy for first-line systemic treatment
  • The researcher believes that the patient is capable of implementing the research protocol

Exclusion

  • Patients has participated in any clinical trial in the past 4 weeks
  • Patients is currently or about to participate in a clinical trial
  • Patients with other malignant tumors (except carcinoma in situ)
  • Patients with lung metastases only
  • Patients with evidence of any serious or uncontrolled systemic disease, including but not limited to: unstable or decompensated respiratory, heart, liver or kidney disease, HIV infection, uncontrolled hypertension, diabetes, severe arrhythmia, massive hemorrhagic activity, etc
  • Patients with history of alcohol or drug abuse
  • According to the researcher's judgment, the possibility of inclusion is low (including inability to understand the study requirements, poor compliance, weakness, inability to ensure that the protocol can be implemented as required, etc.), or the researcher believes that other factors are not suitable for this study

Key Trial Info

Start Date :

May 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 15 2024

Estimated Enrollment :

338 Patients enrolled

Trial Details

Trial ID

NCT04684095

Start Date

May 26 2021

End Date

June 15 2024

Last Update

July 9 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Harbin Medical University Hospital

Harbin, China